FDA
-
-
-
-
-
-
-
Cartesian Therapeutics (RNAC) PT Lowered to $30 at H.C. Wainwright
-
-
-
-
-
-
-
Cartesian Therapeutics (RNAC) Announces First Participant Enrolled in the Phase 3 AURORA Trial of Descartes-08 in Patients with Myasthenia Gravis
-
-
-
-
-
-
-
Cartesian Therapeutics Announces New Employment Inducement Grants
-
-
-
-
-
-
-
Cartesian Therapeutics Announces Positive Updated Results from Phase 2b Trial of Descartes-08 in Participants with Myasthenia Gravis and Outlines Design of Planned Phase 3 Trial
-
-
-
-
-
-
-
Cartesian Therapeutics (RNAC) Receives FDA Rare Pediatric Disease Designation for Descartes-08 for the Treatment of Juvenile Dermatomyositis
-
-
-
-
-
-
-
Mizuho Reiterates Outperform Rating on Cartesian Therapeutics (RNAC)
-
-
-
-
-
-
-
Cartesian Therapeutics (RNAC) Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Descartes-08 for the Treatment of Myasthenia Gravis
-
322,094 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

